IMAGE

Figure 8

ID: ZDB-IMAGE-200410-15
Publication: He et al., 2020 - Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
All Figures: Figures for He et al., 2020

Image

Figure Caption

Figure 8 Schematic diagram depicting the molecular mechanism of <styled-content toggle='no' style='fixed-case'>FST</styled-content> upregulation in <styled-content toggle='no' style='fixed-case'>FLT</styled-content>3/<styled-content toggle='no' style='fixed-case'>ITD</styled-content>‐transgenic zebrafish, knock‐in mice, and human <styled-content toggle='no' style='fixed-case'>AML</styled-content>

Left panel. Transient overexpression of human FLT3/ITD mutation resulted in axis duplication and dorsalization abnormalities in zebrafish accompanied by upregulation of embryonic morphogen Fst. Upregulation of FST was consistently found in FLT3/ITD‐transgenic zebrafish, Flt3/ITD knock‐in mice, FLT3/ITD‐mutated AML cell lines, and primary AML samples in vitro and in vivo. Right panel. A novel FLT3/ITD‐p90RSK‐CREB‐FST signaling cascade was demonstrated in human AML. FST is a promising biomarker and therapeutic target for human FLT3/ITD+ AML.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ EMBO Mol. Med.